Straits Times Index
3,394.21 +17.02 (+0.50%) Nikkei
27,382.56 +19.81 (+0.07%) Hang Seng
22,688.90 +122.12 (+0.54%) FTSE 100
7,765.15 +4.04 (+0.05%) BTC-USD
23,225.72 +116.57 (+0.50%) CMC Crypto 200
526.66 +9.65 (+1.87%)
Exact Sciences Corporation (EXAS)
After hours:
| Previous close | 65.04 |
| Open | 64.15 |
| Bid | 64.25 x 800 |
| Ask | 67.80 x 800 |
| Day's range | 64.00 - 67.58 |
| 52-week range | 29.27 - 84.31 |
| Volume | |
| Avg. volume | 2,719,403 |
| Market cap | 11.99B |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.32 |
| Earnings date | 20 Feb 2023 - 24 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 63.39 |
- Motley Fool
Better Long-Term Buy in 2023: Exact Sciences or Veracyte?
Veracyte (NASDAQ: VCYT) and Exact Sciences (NASDAQ: EXAS) focus on genomic tests to diagnose various cancers. A report by BIS Research puts the molecular cancer diagnostics market at $4.1 billion in 2022 but with a compound annual growth rate (CAGR) of 11.4% through 2032, reaching a $12.1 billion market by that time. Cancer is formed by changes to the genome in a body's cells, leading to uncontrollable growth.
- Motley Fool
Cathie Wood Is Trouncing the Market So Far in 2023 Mainly Due to These 3 Stocks
To be sure, Coinbase still faces significant challenges. The company continues to post steep losses. Wood, though, remains bullish about the stock, and bought additional shares for the ARK Innovation ETF earlier this month.
- Zacks
Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know
Exact Sciences (EXAS) closed at $67.82 in the latest trading session, marking a -0.6% move from the prior day.
